USFDA partially lifts import ban on Ipca Labs APIs of Chloroquine Phosphate and Hydroxychloroquine Sulphate

Mumbai: IPCA Labs has announced that due to the shortage implications and/or medical necessity of certain drugs and finished products, the United States Food and Drug Administration (FDA) vide its e-mails dated 20th March 2020 has made an exception to the import alert for the Company's following Active Pharmaceutical Ingredients (APIs) and finished products (Formulations) :

a. Hydroxychloroquine Sulphate and Chloroquine Phosphate APIs produced at the Company's APIs manufacturing unit situated at Ratlam (Madhya Pradesh); and

b. Hydroxychloroquine Sulphate Tablets produced at the Company's formulations manufacturing units situated at SEZ Indore, Pithampur (Madhya Pradesh) and Piparia (Silvassa).

US FDA has also informed that their exception will be re-considered if the shortage implications change.

"We also wish to bring to your notice several credible articles/reports/research papers claiming prophylactic as well as treatment potentials of Chloroquine Phosphate and Hydroxychloroquine Sulphate formulations in managing/treating Coronavirus Disease (Covid-19), though these drugs are not approved for treatment by any regulatory authority" it stated

Foreseeing this increased demand, Ipca being amongst largest manufacturer, vertically integrated with capacities and capabilities for manufacturing of these APIs and its formulations, is gearing to manufacture and supply these products meeting the stringent cGMP, quality and regulatory requirements and thus help mankind in the best possible way in these testing times.

Read also: Ipca Labs, Medicines For Malaria Venture Ink Pact For Antimalarial Co-Formulation Atoguanil